Biologics The Modern Tool of Wound Closure & Advanced Wound Care Global Market

The wound is a breakdown in the protective function of the skin and loss of connectivity of epithelium by an intentional or unintentional purpose that needs to be closed using different wound care products depending on the condition and span of the wound. Among the types of wound closure products primary closure products are used in the closure of fresh and acute wounds, especially in surgical and trauma laceration applications, whereas, secondary closure products (advanced wound care products) are used in the closure of chronic wounds, due to burns, ulcers, radionecrosis and others. Biologics one among the emerging segment of the secondary wound closure product segment is referred as own bodily components that are intended to facilitate the re-establishment of the innate repair mechanisms and may also involve various applications of active biological agents. These biological agents prevents evaporative water loss, heat loss, protein & electrolyte loss when used in dressing, whereas in other ways it enhances the healing power naturally within short period of time, When compared to other wound closure procedures this technique avoids the chances of contamination, infection and other side effects.

According to IQ4I analysis, the biololgics market in wound closure & advanced wound care global market is expected to grow at a double digit CAGR to reach $1,950.2 million by 2023. Increasing incidence of ageing population and prevalence of lifestyle diseases, increase in surgical procedural volume, an increase in the prevalence of chronic wounds and government funding for R&D activities are some of the factors driving the biologics market. Demand for biologics, the emergence of technically advanced products and acquisitions by market players are some of the opportunities for biologics market. However, lack of trained professional in handling the sophisticated biologics technique, expensive techniques impeding effective penetration in low and middle-income countries are some of the factors hampering the market growth.

Acelity, Ltd and Organogenesis are the major players operating in the biologics segment. Biologics product segment is classified into skin grafts and growth factors, where skin grafts dominates the market by taking the major share of XX%, due to various types of advantages like lack of rejection, minimal secondary contraction and with excellent color match. Whereas, these products are not preferred in the management of complex wounds as only limited supply of donor skin that can be closed directly. These skin grafts are used in the applications of traumatic wounds, defects after oncologic resection and burn reconstruction. Various components like skin correspondents, epidermal growth factors, stem cells and tissues are utilized as skin grafting.

Advancements in technology include liquid skin grafts, stem cell therapy and others. In September 2016, a team of scientists from U.K. National Health Services (NIH) has come up with a device named ReGenerCell, which liquefies the skin sample taken from the patient and allowing it to be sprayed over the wound to enhance the healing process. This device enables the production of a Regenerative Epithelial Suspension (RES), a liquid that contains added wound-healing components essential for natural skin healing. This device is useful in treating chronic or slow healing wounds such as pressure sores and venous leg ulcers.

ExpressGraft by Stratatech Corporation (U.S.), Omega3 Wound by Kerecis (Iceland), Graftjacket Xpress flowable soft tissue scaffold by Acelity, Ltd (U.S.) are some of the products offered by the market players.

Stratatech Corporation (U.S.), Integra Lifesciences (U.S.), Acelity, Ltd (U.S.) and Kerecis (Iceland) are some of the skin graft offering market players.


Leave Your Comment